Statins and blood coagulation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 2, 2005, Pages 287-294

  Undas, Anetta ^a   Brummel Ziedins, Kathleen E ^b   Mann, Kenneth G ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Blood coagulation; Protein C; Statins; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; FIBRIN; FIBRINOGEN; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; LIPOPOLYSACCHARIDE; MEVINOLIN; PROTEIN C; PROTEIN S; SIMVASTATIN; STATIN; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE DISEASE; ANTICOAGULATION; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOWN REGULATION; ENDOTHELIUM CELL; FIBRIN FORMATION; ISOPRENYLATION; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ARTERIOSCLEROSIS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD PROTEINS; FACTOR VII; FIBRINOGEN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, BIOLOGICAL; PROTEIN ISOPRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; STAPHYLOCOCCAL PROTEIN A; THROMBIN; THROMBOMODULIN; THROMBOPHILIA; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 13244292577     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000151647.14923.ec     Document Type: Short Survey

References (81)

1. LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 1999; 282:2340-2346.
2. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systemic review and meta-analysis. BMJ. 2003;326:1423.
3. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 1990;4:3319-3328.
4. Casey PJ. Protein lipidation in cell signaling. Science. 1995;268:221-225.
5. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA. 1998;279: 1643-1650.
6. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21:1712-1719.
7. Undas A, Celinska-Löwenhoff M, Kaczor M, Musial J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004;91:1065-1077.
8. Krysiak R, Okopień B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs. 2003;63:1821-1854.
9. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol. 2000;76:23-32.
10. Brummel-Ziedens KE, Orfeo T, Jenny NS, Everse SJ, Mann KG. Blood coagulation and fibrinolysis. In: Lee GR, Forester J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobes Clinical Hematology. 11th Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
11. Mann KG. The coagulation explosion. Ann N Y Acad Sci. 1994;714:265-269.
12. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999;82:165-174.
13. Morrissey JH. Tissue factor: an enzyme cofactor and true receptor. Thromb Haemost. 2002;86:66-74.
14. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. VA statins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 1997;17:265-272.
15. Hilgendorff A, Muth H, Parviz B, Stauitz A, Haberbosch W, Tillman H, Holschermann H. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003;41:397-401.
16. Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis. 2000;149:111-116.
17. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells. Role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105:1756-1759.
18. Nagata K, Ishibashi T, Sakamoto T, Ohkawara H, Shindo J, Yokoya K, Sugimoto K, Sakarada S, Takuwa Y, Nakamura S, Teramoto T, Maruyama Y. Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. Atherosclerosis. 2002;163:39-47.
19. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
20. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furuka M, Shiomi M, Schoen FJ, Libby P. An HMG-CoA inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103:276-283.
21. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering. Atherosclerosis. 2003;167:187-194.
22. Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in absence of lipid lowering. Arterioscler Thromb Vasc Biol. 2002;22:692-698.
23. Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E, Gabrielli L, Camera M. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost. 2002;88:41-47.
24. Morishita E, Minami S, Ishino C, Kanno M, Uotani C, Asakura H, Matsuda T, Nakao S. Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. J Atheroscler Thromb. 2002;9:72-77.
25. Porreca E, Di Febbo C, Amore C, Di Castelnuovo A, Baccante G, Donati MB, Cuccurullo F, Iacoviello L. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb Haemost. 2000;84: 789-793.
26. Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol. 2000;85:350-353.
27. Sbarouni E, Melissari E, Kyriakides ZS, Kremastinos DT. Effecs of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease. Am J Cardiol. 2000;86: 80-83.
28. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999;33:1294-1304.
29. Gottsater A, Anwaar I, Lind P, Mattiasson I, Lindgarde F. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis. 1999;10:133-140.
30. Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT, Badimon JJ, Ambrose JA. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost. 2000; 83:688-692.
31. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92: 3172-3177.
32. Aoki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, Yanagisawa A, Yamamoto M, Kawai Y, Ishikawa K. Platelet dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol. 1997;30:91-96.
33. Weiss JH, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood. 1988;71:629-635.
34. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001;98:2423-2431.
35. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Dorner GT. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 2001;85:47-51.
36. Alessandri C, Basili S, Maurelli M, Bracaglia D, Andreozzi P, Pergoli M, Cordova C. Relationship between prothrombin activation fragment F1+2 and serum cholesterol. Haemostasis. 1996;26:213-219.
37. Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizuta K, Kato M, Matsuda T, Nakao S. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis. 2001; 154:203-212.
38. Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol. 1999;33:1286-1293.
39. Musial J, Undas A, Undas R, Brozek J, Szczeklik A. Treatment with simvastatin and low dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline high cholesterol levels. Thromb Haemost. 2001;85:221-225.
40. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248-2253.
41. Butenas S, van't Veer C, Mann KG. Evaluation of the initial phase of blood coagulation using ultrasensitive assays for serine protease. J Biol Chem. 1997;272:2169-2178.
42. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost. 1999;82:987-1004.
43. Olivotti L, Ghigliotti G, Spallarossa P, Leslie S, Rossettin P, Barsotti A, Brunelli C. High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. Blood Coagul Fibrinolysis. 2002;13:315-322.
44. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischaemia and Function of the Endothelium) trial. Circulation. 1999;99:3227-3233.
45. Minami T, Sugiyama A, Wu S-Q, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol. 2004;24:41-53.
46. Takeya H, Gabazza EC, Aoki S, Ueno H, Suzuki K. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood. 2003;102:1693-1700.
47. nd, Shen GX, Minnear FL, Brezniak DV, Walenga JM, Bognacki JJ, Ofosu FA. Statins induce hypothrombotic states? Clin Appl Thromb Hemost. 2000;6:18-21.
48. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci. 2001;936:11-30.
49. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem. 1999;274:22862-22870.
50. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effects on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol. 1991;31:512-517.
51. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, Hafner G, Treude R, Othman H, Hoffmann KP, Meyer J; AtheroGene Investigators. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, leucocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:901-908.
52. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997; 79:1475-1481.
53. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen levels and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 1996; 122:225-233.
54. Marais AD, Firth JC, Bateman ME, Bynes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arteroscler Thromb Vasc Biol. 1997;7:1527-1531.
55. Bertolotto A, Bandinelli S, Ruocco L, Lo Faro A, Penno G, Navalesi R. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis. 1999;143:455-457.
56. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Haematol. 1993;44:112-116.
57. Muszbek L, Yee LC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94:271-305.
58. Ariëns RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100:743-754.
59. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:1-9.
60. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 2003;1: 1515-1524.
61. Esmon CT The protein C pathway. Chest 2003;124(3 suppl):26S-32S.
62. Ambrosi P, Aillaud MF, Habib G, Kreitmann B, Metras D, Luccioni R, Bouvenot G, Juhan-Vague I. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost. 2000;83: 46-48.
63. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary artery disease. Atherosclerosis. 2002;162:179-185.
64. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512-517.
65. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric-oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003;14:575-585.
66. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
67. Hockin MF, Kalafatis M, Shatos M, Mann KG. Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:2765-2775.
68. Tracy PB, Nesheim ME, Mann KG. Proteolytic alterations of factor Va bound to platelets. J Biol Chem. 1983;258:662-669.
69. Golino P. The inhibitors of the tissue factor:factor VII pathway. Thromb Res. 2002;V257-V265.
70. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipidemia. Arterioscler Thromb Vasc Biol. 1995;15:879-885.
71. Lorena M, Perolini S, Casazza F, Milani M, Cimminiello C. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Thromb Res. 1997;87:397-403.
72. Bo M, Bonino F, Neirotti M, Gottero M, Pernigotti L, Molaschi M, Fabris F. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology. 1991;42:106-113.
73. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled study. JAMA. 2001;285:1711-1718.
74. Stenestrand U, Wallentin L, for the Swedish Registry of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and one-year survival. JAMA. 2001;285:430-436.
75. Langer A, Constance C, Fodor JG, Frohlich JJ, Gregoire J, Lau DCW, Leiter LA, Mancini J, Marr D, McPherson R, O'Neill BJ, Rabkin SW. Statin therapy and the management of acute coronary syndromes. Can J Cardiol. 2003;19:921-927.
76. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
77. Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res. 1997;88:67-73.
78. Grady D, Weger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolism. Ann Intern Med. 2000;132:689-696.
79. Ray JG, Mamdani M, Tsuyaki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161:1405-1410.
80. Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, Rosendaal FR, Psaty BM. HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost. 2004;2:700-701.
81. Yang C-C, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 2002;53:101-105.